Synaptic dysfunction and loss appears central to clinical deficits in Alzheimer's disease (AD), but the causes of synapse loss and methods of intervention are poorly understood. Oxidative damage to proteins, DNA, RNA and lipids is increased in AD brain, including large increases in oxidized docosahexaenoic acid (DHA), an essential omega-3 fatty acid required for synaptic function. Our preliminary data show that a diet deficient in DHA results in CNS depletion of DHA, increased oxidative damage, caspase activation, Abeta accumulation and dramatic postsynaptic marker loss selectively in aging APPsw transgenic animals. DHA and synaptic marker losses in transgene positive animals correlate with increased oxidative damage. Our central hypothesis is that focal synaptic oxidative damage due to local Abeta42 accumulation drives a positive feedback loop resulting in increased Abeta production, oxidative damage, synaptic dysfunction and selective postsynaptic marker loss. Relevance to AD is supported by increased oxidized DHA, selective postsynaptic marker loss and flow cytometric evaluations showing increased synaptosomal apoptotic mitochondrial marker and Abeta labeling in AD vs. controls. Available results argue that supplemental Vit E, currently the standard treatment for oxidative damage in AD, may offer only limited protection against peroxynitrite, DHA oxidation, synaptic damage and clinical progression. In contrast, our animal model data show the phenolic antioxidant, curcumin, affords strong protection against multiple putative amyloid cascade endpoints including oxidative damage, inflammation (IL-1beta, TNF-a, CD11b, iNOS), amyloid accumulation, postsynaptic marker loss and cognitive deficits. By measuring the treatment's impact on CNS pathologic markers in animal models, we expect to validate accessible, but indirect or """"""""surrogate"""""""" measures in humans that will be useful in assessing efficacy in clinical trials. We will test our central hypothesis using animal models to define optimum antioxidant treatments that ameliorate amyloidosis, oxidative damage and synaptic pathology in AD and confirm clinical relevance of the implicated biochemical pathways using AD tissue from the Neuropathology and Molecular Genetics Core.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016570-09
Application #
7393172
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
9
Fiscal Year
2007
Total Cost
$237,058
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Joe, Elizabeth; Medina, Luis D; Ringman, John M et al. (2018) 1H MRS spectroscopy in preclinical autosomal dominant Alzheimer disease. Brain Imaging Behav :
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679

Showing the most recent 10 out of 727 publications